Brexpiprazole HCl

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Brexpiprazole (OPC-34712)，一种非典型的、具有口服活性的抗精神紊乱剂，是人 5-HT1A 和多巴胺受体（dopamine D2L receptor）的部分激动剂，Ki 分别为 0.12 nM 和 0.3 nM。Brexpiprazole 也是 5-HT2A 受体的拮抗剂，Ki 为 0.47 nM。Brexpiprazole 对人去甲肾上腺素能受体 α1B (Ki=0.17 nM) 和 α2C (Ki=0.59 nM) 也显示出强效拮抗活性。

Brexpiprazole is a new antipsychotic drug.

Brexpiprazole (0-1.0 μM, 4 days) potentiates NGF-induced neurite outgrowth in a dose-dependent manner in PC12 cells.

Brexpiprazole (0-0.1 mg/kg; p.o.; once) improves social recognition deficits in mice. Animal Model:Male C57BL/6NCrSlc mice, Dizocilpine (0.1 mg/kg) (HY-15084B) induced social recognition deficits Dosage:0.01, 0.03 and 0.1 mg/kg Administration:Oral administration, once Result:Significantly ameliorated Dizocilpine-induced social recognition deficits, without sedation or a reduction of exploratory behavior.

OPC 34712 dihydrochloride

Others

Other Targets

Others

——

——

913612-38-1

433.6

C25H27N3O2S.xHCl

>98% (HPLC)

——

Cl.O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1

——

(-20℃)

With Ice Pack

≥ 2 years